1 **Title:** Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus
2 chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort
3 study
4
5 **Running title:** PD-(L)1 blockade with or without chemotherapy in lung
6 adenocarcinomas
7

Authors: Arielle Elkrief, MD*[1,2,5], Joao M. Victor Alessi, MD*[3], Biagio Ricciuti, MD*[3],
Samantha Brown, MS[4], Hira Rizvi, MS[5], Isabel R. Preeshagul, MD[5], Xinan Wang, PhD,
MS[7], Federica Pecci, MD[3], Alessandro Di Federico, MD[3], Giuseppe Lamberti, MD[3],
Jacklynn V. Egger, MSc[5], Jamie E. Chaft, MD[5], Charles M. Rudin, MD, PhD[5,6], Gregory
J. Riely, MD, PhD[5,6], Mark G. Kris, MD[5,6], Marc Ladanyi, MD[1,2], Yuan Chen, PhD[4],
Matthew D. Hellmann, MD[5,6] Ronglai Shen, PhD*[4], Mark M. Awad, MD, PhD*[3], Adam J.
Schoenfeld, MD*[5,6]
15
Affiliations:
1. Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY
2. Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis
Program, New York, NY
3. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
4. Memorial Sloan Kettering Cancer Center, Department of Epidemiology &
Biostatistics, New York, NY
5. Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY
6. Weill Cornell Medical College, Department of Medicine, New York, NY, USA
7. Harvard T.H. Chan School of Public Health, Harvard Univeristy, Department of
Environmental Health, Boston, MA
27
28 **Corresponding author:**
29 Adam J. Schoenfeld
30 1275 York Ave, New York, NY 10065
31 Phone: 6466084042
32 Email: schoenfa@mskcc.org
33
34 *Contributed equally

35
36 **Key words: Lung cancer, immunotherapy, combination therapy**

47
48 **Ethics approval and consent to participate:** This study was approved by the
49 institutional review board at Memorial Sloan Kettering Cancer Center (16-1144) and
50 Dana Farber Cancer Institute (02-180, 11-104, 17-000).
51
52 **Consent to publish:** Not applicable.
53
54 **Availability of data and material:** All code used for analysis and figure generation will
55 be made available. Clinical data available upon request to the corresponding author.
56
Competing interests: JEC has consulted for: AstraZeneca, BMS, Genentech, Merck,
Flame Biosciences, Regeneron-Sanofi, Guardant Health, Arcus Biosciences and also
declared research funding to institution from: AstraZeneca, BMS, Genentech, Merck,
Novartis. CMR has consulted with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo,
Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck, and Syros. He serves on
the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics.
GJR reports institutional research support from Mirati, Lilly, Takeda, Merck, Roche,
Pfizer, and Novartis. MGK reports honoraria from AstraZeneca, Pfizer, Merus, and
BerGenBio. MDH reports grants from BMS; and personal fees from Achilles; Adagene;
Adicet; Arcus; AstraZeneca; Blueprint; BMS; DaVolterra; Eli Lilly; Genentech/Roche;
Genzyme/Sanofi; Janssen; Immunai; Instil Bio; Mana Therapeutics; Merck; Mirati;
Natera; Pact Pharma; Shattuck Labs; and Regeneron; as well as equity options from
Factorial, Immunai, Shattuck Labs, Arcus, and Avail Bio. A patent filed by Memorial
Sloan Kettering related to the use of tumor mutational burden to predict response to
immunotherapy (PCT/US2015/062208) is pending and licensed by PGDx. Subsequent
to the completion of this work, MDH began as an employee (and equity holder) at
AstraZeneca. MMA reports that he was a consultant to: Bristol-Myers Squibb, Merck,
Genentech, AstraZeneca, Mirati, Novartis, Blueprint Medicine, Abbvie, Gritstone,
NextCure, EMD Serono and received research funding (to institute) from: Bristol-Myers
Squibb, Eli Lilly, Genentech, AstraZeneca, Amgen. AJS reports consulting/advising role
to J&J, KSQ therapeutics, BMS, Merck, Enara Bio, Perceptive Advisors, Oppenheimer
and Co, Umoja Biopharma, Legend Biotech, Iovance Biotherapeutics, Lyell
Immunopharma and Heat Biologics, research funding from GSK (Inst), PACT pharma
(Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), BMS
(Inst), Harpoon Therapeutics (Inst) and Amgen (Inst). AJS reports consulting/advising
role to J&J, KSQ therapeutics, BMS, Merck, Enara Bio, Perceptive Advisors,
Oppenheimer and Co, Umoja Biopharma, Legend Biotech, Iovance Biotherapeutics,
Lyell Immunopharma and Heat Biologics. Research funding: GSK (Inst), PACT pharma
(Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), BMS
(Inst), Harpoon Therapeutics (Inst) and Amgen (Inst).
87
Funding: AE effort funded by the Canadian Institutes of Health Research, the Royal
College of Surgeons and Physicians of Canada, and the Henry R. Shibata Fellowship.
XW effort funded by: National Institutes of Health grant U01CA209414. MMA effort was
funded by: V Foundation, Elva J. and Clayton L. McLaughlin Fund for Lung Cancer
Research. This study was funded by National Institute of Health grants (cancer center

grant P30CA008748 to MSKCC) and philanthropy (grants from John and Georgia
DallePezze to MSKCC, The Ning Zhao & Ge Li Family Initiative for Lung Cancer
Research and New Therapies, and the James A. Fieber Lung Cancer Research Fund).
96

Author contributions:
Study conducts and design**:** JVA, AE, BR, SB, YC, RS, AJS, MMA; data acquisition:
JVA, AE, BR, HR, JVE; statistical analysis: JVA, AE, BR, SB, YC, RS; data
interpretation: JVA, AE, BR, SB, YC, JVA, AE, BR, SB, YC, RS RS, AJS, MMA; drafting
the manuscript or revising it critically: all authors; final approval of the manuscript: all
authors.
103

104   **Acknowledgements:**The authors wish to acknowledge Clare Wilhelm for editorial
105   support. The authors wish to acknowledge the support of the Center Core grant (P30
106   CA008748), the Molecular Diagnostics Service in the Department of Pathology, and the
107   Marie-Josee and Henry R. Kravis Center for Molecular Oncology.
108

109 **List of abbreviations**
110

NSCLC	Non-small cell lung cancer
LUAD	Lung adenocarcinoma
IO	Anti-PD-(L)-1 monotherapy
Chemotherapy-IO	Combination anti-PD-(L)-1 with platinum-doublet chemotherapy
ORR	Overall response rate
PFS	Progression-free survival
OS	Overall survival
HR	Hazard ratio
95%CI	95% confidence interval
NGS	Next-generation sequencing
PD-L1 TPS	PD-L1 tumor proportion score

ABSTRACT

Background: Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) are approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression $\geq$1%. These regimens have not been compared prospectively. The primary objective was to compare first-line efficacies of single-agent IO to Chemotherapy-IO in patients with advanced LUADs. Secondary objectives were to explore if clinical, pathologic, and genomic features were associated with differential response to Chemotherapy-IO vs IO.

Methods: This was a multicenter retrospective cohort study. Inclusion criteria were patients with advanced LUADs with tumor PD-L1 $\geq$1% treated with first-line Chemotherapy-IO or IO. To compare the first-line efficacies of single-agent IO to Chemotherapy-IO, we conducted inverse probability weighted (IPW) Cox proportional hazards models using estimated propensity scores.

Results: The cohort analyzed included 874 patients. Relative to IO, Chemotherapy-IO was associated with improved ORR (44% vs 35%, p=0.005) and PFS in patients with tumor PD-L1$\geq$1% (HR 0.75, 95% CI 0.0.61-0.92, p=0.005) or PD-L1$\geq$50% (ORR 55% vs 38%, p<0.001; PFS HR 0.74 95%CI 0.56-0.97, p=0.032). Using propensity-adjusted analyses, only never smokers in the PD-L1 $\geq$50% subgroup derived a differential survival benefit from Chemotherapy-IO vs IO (p=0.03). Among patients with very high tumor PD-L1 expression ($\geq$90%) there were no differences in outcome between treatment groups. No genomic factors conferred differential survival benefit to Chemotherapy-IO vs IO.

Conclusions: While the addition of chemotherapy to PD-(L)1 blockade increases the probability of initial response, never-smokers with tumor PD-L1 $\geq$50% comprise the only population identified that derived an apparent survival benefit with treatment intensification.

Introduction

Drugs that inhibit PD-1 or PD-L1 (PD-(L)1 blockade) have transformed the

treatment landscape for patients with advanced non-small cell lung cancer (NSCLC)

without targetable driver mutations. In 2022, there are several US Food and Drug

Administration-approved first-line PD-(L)-1 blockade regimens alone (IO) or in

combination with platinum-doublet chemotherapy (Chemotherapy-IO), all of which

demonstrated clinical benefit compared to chemotherapy[1-7]. The increased breadth of

treatment options in newly diagnosed advanced lung cancer and lack of published

head-to-head trials makes regimen selection challenging. It is unclear if certain

populations might derive similar or greater clinical benefit from IO monotherapy than

Chemotherapy-IO, and might thereby avoid the potential toxicities of chemotherapy.

Prior studies have identified clinical and genomic factors associated with efficacy

of PD-(L)1 blockade. Eastern Cooperative Oncology Group (ECOG) performance

status, smoking history, PD-L1 expression, and tumor mutational burden (TMB)

influence clinical activity and outcomes[8-10]. NSCLCs harboring mutations in *STK11*

and/or *KEAP1* have worse outcomes to PD-(L)1 blockade, particularly among *KRAS*-

mutant NSCLCs[11]. In these cases, addition of chemotherapy might overcome IO

resistance[11]. Conversely, other factors such as poor performance status may limit

tolerability of chemotherapy and negate potential additive anti-cancer activity of

combination therapy[12].

We posited that clinical, pathologic, and molecular analyses of a real-world

patient population could identify patient subpopulations that might differentially benefit

from IO vs Chemotherapy-IO in the first-line setting. In order to address biases and

differences in baseline characteristics between the IO and Chemotherapy-IO groups,

we performed propensity-adjusted analyses in 874 patient cases of lung

adenocarcinoma (LUAD) without *EGFR* or *ALK*-sensitizing alterations treated with IO or

Chemotherapy-IO at two institutions.

METHODS

Patients

After institutional review board approval, patients with advanced LUAD from Memorial

Sloan Kettering Cancer Center [MSK] and Dana-Farber Cancer Institute [DFCI]

between 2011-2020 were assessed in this retrospective analysis. Only patients with

advanced lung adenocarcinoma treated in the first-line with IO or Chemotherapy-IO

were eligible for analysis (**Figure S1**).

PD-L1 expression (tumor proportion score) was evaluated in all patients included

in the study and reported as the percentage of tumor cells with membranous staining as

previously described[13]. For genomic analyses, only patients with genomic sequencing

by MSK-IMPACT (MSK) or OncoPanel (DFCI) NGS panels were included[14,15]

(**Supplemental Methods)** TMB was harmonized for comparison as previously

published (**Supplemental Methods**)[16]. Patients with tumors with PD-L1 <1% or

harboring sensitizing *EGFR* or *ALK* alterations were excluded. Pre-planned analyses in

PD-L1 1-49% and $\geq$50% subgroups were conducted to align with current first-line

treatment guidelines[17]. The primary outcomes were objective response rate (ORR),

progression-free survival (PFS), and overall survival (OS).

Statistical Analysis

Descriptive statistics were used to describe the analysis population by treatment group

(Chemotherapy-IO vs IO). Differences in baseline characteristics by group were

evaluated using the Wilcoxon rank sum test, Fisher's exact test, or Pearson's Chi-

squared test as appropriate.

Patients who did not experience progression or death by the data lock date

(October 21st, 2021) were censored at date of last assessment. Investigator-assessed

ORR was defined as the rate of partial response + complete response. Real-world

investigator-assessed PFS was assessed from the date the patient began therapy to

the date of progression as previously described as per RECIST v1.1[18-20]. OS was

calculated from treatment start date until date of death or last assessment. Kaplan-

Meier curves and log-rank test statistics were computed to compare PFS and OS

between groups.

We conducted propensity score modelling for treatment group assignment using

a logistic regression model with the following potential prognostic factors as categorical

variables: age ($\geq$65 vs <65), Eastern Cooperative Oncology Group performance status

(ECOG; scores 2-3 vs scores 0-1), smoking status (current/former smokers vs. never

smokers), PD-L1 tumor proportion score percentage (PD-L1 $\geq$50% vs PD-L1 1-49%),

and presence of liver or brain metastases at baseline. To account for the potential

difference in treatment assignment, we conducted inverse probability weighted (IPW)

Cox proportional hazards models using the estimated propensity scores. Three sets of

IPW Cox models were explored. The first model (**main effects model**) contained

treatment group along with clinical categorical variables (age, ECOG, smoking status,

PD-L1 %, baseline liver metastases and baseline brain metastases) to examine the

overall treatment effects on PFS and OS. The second model (**treatment interaction**

model) further included interactions between treatment group and clinical variables to

examine treatment effect modifications, to identify subgroups for differential benefit of

Chemotherapy-IO vs IO. The third model was restricted to patients with genomic data

available, building off our second model (**treatment interaction model, genomics**

analysis cohort) with the additions of the following categorical variables: harmonized

TMB score (see **Supplemental Methods**) and five gene mutations (*KRAS*, *TP53*,

KEAP1, *STK11*, and *SMARCA4*), as well as their interactions with treatment group. The

five gene mutations were selected as they have previously been associated with IO

outcomes in lung cancer[21-23]. For each clinical subgroup of interest, we calculated the

hazard ratio for treatment group (Chemotherapy-IO vs IO) adjusting for all clinical

covariates included in the propensity score IPW Cox proportional hazards model, and

visualized these results using forest plots.

Analyses were conducted using R version 4.1.1 with the tidyverse (v1.3.1)[24],

gtsummary (v1.6.0)[25], survival (v3.3.1) and survminer (v0.4.9) packages[26].

Results

Patient Characteristics

Among all patients with advanced LUAD treated with Chemotherapy-IO or IO without a

targetable driver alteration in *EGFR* or *ALK*, 874 patients met criteria for inclusion

(**Figure S1**). Median follow-up for the clinical analysis cohort was 23 months (IQR: 12,

38); 397 (45%) patients were treated with Chemotherapy-IO and 477 (55%) were

treated with IO (**Table 1**). Relative to the Chemotherapy-IO group, patients in the IO

group were slightly older (median age 69 vs 67, p<0.001) with a more frequent and

heavier smoking history (median pack years 30 vs. 25 p=0.022) (**Table 1**). PD-L1 high

expression (>50%) was enriched within the IO group relative to the Chemotherapy-IO

group (84% vs 29% with PD-L1 high, p<0.001) (**Figure S2A**)[17]. Median harmonized

TMB score (0.09 vs -0.05, p=0.023) was also significantly higher in the IO group (**Figure**

S2B) Other baseline clinical factors such as ECOG performance status and sex were

similarly distributed between the Chemotherapy-IO and IO groups (**Table 1**).

Clinical Outcomes

Among 874 patients with PD-L1 ≥1% LUAD who were treated with Chemotherapy-IO or

IO in the first-line setting, Chemotherapy-IO was associated with improved ORR (44%

vs 35%, p=0.005) (**Figure 1A**) and improved PFS (median PFS 6.9 (95% CI: 6.0, 8.5)

vs 4.9 months (95% CI: 4.0, 5.8), p=0.015) (**Figure 1B**). There was no difference in OS

between the Chemotherapy-IO vs IO groups (median OS 17 months, 95% CI: 15, 22) vs

20 months (95% CI: 17, 24), p=0.50) (**Figure 1C**). Examining subgroups of interest, age

<65 (HR 0.59, 95%CI 0.42-0.8), and never smoking status (0.43 95%CI 0.22-0.83) were

particularly associated with improved PFS among patients on Chemotherapy-IO (**Figure**

1D). No subgroup conferred differential survival benefit to Chemotherapy-IO vs IO

(**Figure 1E**).

In the IPW propensity-adjusted analysis, current/former smokers (OR 0.48,

95%CI 0.28-0.79, p=0.004) those with tumor PD-L1 ≥50% (OR 0.07, 95% CI 0.05-0.10,

p<0.001) were more likely to receive IO than Chemotherapy-IO (**Table S1**). The results

for the main effects model are shown in **Table S2 and Table S3**. In the treatment

interaction model, Chemotherapy-IO was associated with superior PFS compared to IO

alone (HR 0.38, 95% CI 0.17-0.86, p=0.020) (**Table S4**). No subgroups demonstrated

differential PFS benefit for Chemotherapy-IO or IO (**Table S4**).). There was no OS

benefit associated with Chemotherapy-IO (HR 0.92, 95% CI 0.42-2.00, p=0.824) (**Table**

S5). No subgroups demonstrated differential OS benefit to Chemotherapy-IO or IO

(**Table S5**).). In sum, among patients with PD-L1 ≥1%, Chemotherapy-IO demonstrated

a PFS benefit in a propensity-matched analysis; however, there was no OS benefit

associated with Chemotherapy-IO compared to IO monotherapy.

Clinical Outcomes by PD-L1 Subgroup

Among 519 patients with tumor PD-L1 ≥50%, Chemotherapy-IO was associated

with improved ORR (55% vs 38%, p<0.001) (**Figure 2A**) and PFS (median PFS 10.0

(95% CI: 6.9, 16.0) vs 4.9 months (95% CI: 3.9, 6.2), p=0.002) (**Figure 2B**). There was

no significant difference in OS between the Chemotherapy-IO vs IO groups (median OS

32 (95% CI: 20, not reached (NR)) vs 20 months (95% CI: 17, 26), p=0.40) (**Figure 2C**).

Examining subgroups of interest, never-smokers (HR 0.29, 95%CI 0.16, 0.55) and

younger patients <65 years of age (HR 0.47 95%CI 0.31, 0.71), had improved PFS to

Chemotherapy-IO vs IO (**Figure 2D**).

In the IPW propensity-adjusted analysis, patients who were younger (<65 years

of age) (HR 0.58, 95%CI 0.38-0.90, p=0.015) or who were never-smokers (HR 0.52,

95% CI 0.28- 1.01, p=0.045) were more likely to receive Chemotherapy-IO (**Table S6**).

The results for the main effects model are shown in **Table S7 and Table S8.**

We found significant treatment effect modification factors shown in the treatment

interaction model in this PD-L1$\geq$50% subgroup (**Table S9**) Specifically, the

Chemotherapy-IO PFS benefit over IO alone was more evident in never-smokers

(p=0.0089) (**Table S9**). Age was identified as a significant treatment modifier as well

(p=0.0325, **Table S9**). Specifically, the Chemotherapy-IO benefit over IO alone was

more evident in the younger age group (<65 years) (**Table S9**). There was no significant

difference in OS for Chemotherapy-IO vs IO overall (HR 0.36, 95%CI 0.12-1.10,

p=0.0718) (**Table S10**). Never-smokers derived an OS benefit to Chemotherapy-IO vs

IO (HR 2.98, 95%CI 1.08-7.9, p=0.034) (**Table S10**). Examining clinical outcomes in

these subgroups in greater detail, ORR in never-smokers was higher with

Chemotherapy-IO vs IO group (76% vs 20%, p<0.001, respectively) (**Figure 3A**).

Median PFS among never-smokers in the Chemotherapy-IO vs IO group was 10.0

months vs 2.2 months, respectively (**Figure 3B**). ORR among patients <65 years of age

in the Chemotherapy-IO vs IO groups was higher (63% vs 40%, respectively; p=0.004)

(**Figure 3D**). Median PFS among <65 years of age in the Chemotherapy-IO vs IO group

was 17.0 months vs 4.6 months, respectively (**Figure 3E**). Taken together, these results

suggest that in the PD-L1 $\geq$50% subgroup, there was a PFS benefit in never-smokers

and in younger adults, and OS benefit in never-smokers favoring Chemotherapy-IO

compared to IO.

Next, since very high PD-L1% (≥90%) has previously been associated with

improved outcomes to IO[27], we explored this group in our dataset. Among patients with

very high tumor PD-L1 expression (≥90%, N=214) there was no difference in ORR

(p=0.2) (**Figure S3A**), PFS (p=0.15) (**Figure S3B**) or OS (p=0.4) (**Figure S3B**) between

the Chemotherapy-IO or IO groups.

Lastly, in the PD-L1 1-49% subgroup (N=355 patients), Chemotherapy-IO was

associated with improved ORR (39% vs 19%, p<0.001) (**Figure S4A**) and PFS (median

PFS 6.2 (95% CI: 5.5, 7.5) vs 4.4 months (95% CI: 3.4, 6.7), p=0.016) (**Figure S4B**)

compaed to IO. There was no difference in OS between the Chemotherapy-IO vs IO

groups (median OS 15 (95% CI: 13, 19) vs 17 months (95% CI: 10, 24), p=0.7) (**Figure**

S4C). IPW propensity-adjusted analysis and treatment interaction models for the PD-L1

subgroup are presented in **Tables S11-S15;** there was no differential benefit to

Chemotherapy-IO compared to IO in this subgroup for PFS or OS in any subgroup

examined.

Differential genomic biomarkers of response to Chemotherapy-IO vs IO

There were 579 patients with tumor PD-L1 ≥1% who were treated with

Chemotherapy-IO (N=263) or IO (N=316) and underwent genomic sequencing (**Table**

S1, genomic analysis cohort). Median follow-up for the genomic analysis cohort was 24

months (IQR: 13, 40). Patient baseline characteristics for the genomic analysis cohort

were similar to the clinical analysis cohort (**Table S16**).

There were no differences in ORR between Chemotherapy-IO and IO within

different mutation subgroups of interest in *KRAS, TP53, SMARCA4, KEAP1, STK11, or*

TMB (**Figure 4A**). In propensity-adjusted analyses, significant treatment effect modifiers

were found. Specifically, the Chemotherapy-IO benefit over IO alone was more evident

in patients with higher harmonized TMB score (p=0.002) (**Table S17**). Conversely, the

Chemotherapy-IO benefit over IO alone was reduced in patients with *SMARCA4*

mutations (p=0.011) (**Table S17**). No significant differential OS benefit to

Chemotherapy-IO vs IO was found among patients with mutations in *KRAS*, *KEAP1*,

STK11, or *TP53* or among TMB thresholds (**Table S18**). Examining the significant

covariates conferring differential initial benefit to Chemotherapy-IO vs IO further, there

were no differences in PFS or OS among patients with either high or low median TMB

(**Figure 4B-E**). Patients with *SMARCA4* had numerically improved median PFS (**Figure**

4F) and OS (**Figure 4G**) to IO compared to Chemotherapy-IO.

Discussion and conclusion

We examined the efficacy of IO compared to treatment intensification with

Chemotherapy-IO, in the context of key clinical and molecular features of LUAD. Within

the PD-L1 ≥50% subgroup, we found the addition of chemotherapy to PD-(L)1 blockade

led to improvements in ORR and PFS, but this only translated into an OS benefit in

never-smokers. The only population that did not derive any initial benefit to

Chemotherapy-IO over IO was the PD-L1 very high (≥90%) subgroup.

Our analyses inform potential rational strategies to select and sequence available

therapies for patients with advanced lung cancers without targetable driver mutations.

The lack of superior survival with Chemotherapy-IO compared to IO supports the notion

that, biologically, chemotherapy and immunotherapy may be working independently and

additively rather than generating synergistic immunologic activity[28]. The addition of

chemotherapy increases the probability of initial response in a heterogenous patient

population with differential sensitivity to chemotherapy and immunotherapy, but long-

term benefit appears largely driven by whether PD-(L)1 blockade generates durable

anti-tumor immunity. The lack of OS benefit with Chemotherapy-IO compared to IO in

our overall study population is also supported by recent clinical analyses of real-world

and randomized-controlled trials in patients with PD-L1 $\geq$50% non-squamous NSCLC

[18,29]. In these circumstances, deeper investigation of clinical and genomic factors

associated with differential benefit with Chemotherapy-IO compared to IO is helpful to

optimize regimen selection.

We initially hypothesized that distinct clinical and molecular characteristics

previously associated with IO resistance (for example, baseline liver metastases,

STK11, and/or *KEAP1* mutations) might distinguish patient populations that would

benefit from treatment intensification with Chemotherapy-IO [11]. Contrary to our

hypothesis, we found that while factors such as liver metastases and *STK11* mutations

were associated with poor response overall, they did not confer superior long-term

benefit from Chemotherapy-IO. Thus, treatment escalation with chemotherapy may not

be sufficient or indicated solely based upon these factors. Conversely, predictors of

durable benefit from IO such as very high PD-L1% ($\geq$90%) may be a useful indicators of

when IO monotherapy is appropriate[30]. For this select group of patients, we found no

difference in initial response between the Chemotherapy-IO or IO groups. Interestingly,

our study also found that patients with *SMARCA4* mutations experienced better

response rates and PFS with IO compared to Chemotherapy-IO. The clinical implication

of this observiation is supported by prior studies, which have identified *SMARCA4*

mutation as a poor prognostic factor, potentially associated with resistance to

chemotherapy[31,32] but improved response to IO [17]. However, only 12% of patients had

SMARCA4 mutations. More extensive molecular and gene expression analyses may be

helpful in determining if specific genomic signatures benefit differentially from

Chemotherapy-IO vs IO, but these analyses require much larger sample size for

adequate power in the face of multiple hypothesis testing.

Never smoking status emerged as the primary factor associated with survival

benefit favoring Chemotherapy-IO within the PD-L1 $\geq$50% subgroup. Prior studies have

found a correlation between smoking history and increased TMB and that smoking

history could be a potential clinical surrogate for TMB[33,34]. However, here we found that

even when accounting for TMB in a propensity adjusted model, smoking status

remained a distinct predictive factor. Smoking history is a readily available biomarker

that could be of value in determining regimen selection. Our analysis suggests that

Chemotherapy-IO should be strongly considered for never-smokers even in the

presence of high TMB and/or PD-L1 expression. Further work is needed to identify the

underlying biologic basis for this pattern.

The increased response rate and PFS benefit generally observed with

Chemotherapy-IO suggests that therapeutic escalation could have an important role in

aggressive or extensive disease. Here, the addition of chemotherapy could help provide

more immediate symptom relief. Further, these patients may not otherwise have the

opportunity to receive salvage chemotherapy after progression on immunotherapy. In

this scenario, initial disease control with chemotherapy could create a window of

disease control to enable the more gradual effects of IO to become operant. Notably,

however, in the setting of brain or liver metastases, we did not find any clinical benefit

from the addition of chemotherapy to IO, consistent with prior analysis[35]. In this setting,

it is unclear if the added toxicity that comes with chemotherapy may abrogate the

potential clinical benefits. Further investigation is also needed to understand the precise

impact of volume of disease on patient outcomes.

Our study is a retrospective analysis with the associated limitations, but we

sought to minimize inherent bias by including two large institutions and by applying

robust propensity-matching methodology. The modest sample size of the PD-L1 1-49%

subgroup, especially within the patients who received single-agent IO limited the power

of the analysis for this sub-population. Despite these limitations, our study is the first to

comprehensively study the comparative effectiveness of Chemotherapy-IO across all

relevant PD-L1 subgroups, integrating TMB and genomic analyses for the first time.

Our study highlights the critical nature of ongoing clinical trials prospectively

evaluating the comparative effectiveness of anti-PD-(L)1 with and without chemotherapy

(NCT03793179, NCT04547504). Our population included patients often not well-

represented in randomized-controlled trials. These trials exclude patients with ECOG

performance status of ≥2 and patients with active, untreated, or symptomatic brain

metastases. Our study population comprised 15% with ECOG performance status ≥2

and 30% with baseline brain metastases.

In conclusion, we observed improvements in ORR and PFS associated with

Chemotherapy-IO compared to IO, particularly in young, never-smokers. Never smoking

status in the PD-L1 ≥50% subgroup was the only characteristic in which ORR and PFS

improvement translated into a survival benefit. No genomic alterations favored overall

survival with Chemotherapy-IO compared to IO. Our findings demonstrate that the

addition of chemotherapy to PD-(L)1 blockade generally increases the probability of

initial response, but leads to improved survival only among never-smokers in the PD-L1

≥50% subgroup.

Figure Legends

Figure 1. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade

(Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in patients with PD-

L1≥1%. A. Objective response rate, **B.** Progression-free survival (PFS), and **C.** Overall

survival (OS) among patients with tumor PD-L1≥1% who received first-line

Chemotherapy-IO (N=397) vs IO (N=477). **D.** PFS and **E.** OS analysis for

Chemotherapy-IO vs IO adjusting for co-variates of interest among different subgroups.

Median survival times presented with confidence intervals in brackets. ECOG; Eastern

Cooperative Oncology Group performance status. HR; hazard ratio. 95%CI; 95%

confidence intervals.

Figure 2. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade

(Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in patients with PD-

L1≥50%. A. Objective response rate, **B.** Progression-free survival and **C.** Overall

survival among patients with tumor PD-L1≥50% who received first-line Chemotherapy-

IO (N=117) vs IO (N=402). **D.** PFS and **E.** OS analysis for Chemotherapy-IO vs IO

adjusting for co-variates of interest among different subgroups.

Median survival times presented with confidence intervals in brackets. ECOG; Eastern

Cooperative Oncology Group performance status. HR; hazard ratio. 95%CI; 95%

confidence intervals.

Figure 3. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade

(Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in patients with PD-

L1≥50% in subgroups of interest. A. Objective response rate, **B.** Progression-free

survival (PFS), and **C.** Overall survival (OS) between Chemotherapy-IO vs IO groups in

never smokers with tumor PD-L1≥50%. **D.** Objective response rate, **E.** PFS, and **F.** OS

between Chemotherapy-IO vs IO groups in patients <65 years of age with PD-L1≥50%.

Median survival times presented with confidence intervals in brackets.

Figure 4. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade

(Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in the genomic analysis

cohort (PD-L1≥1%). A. Objective response rate among genomic subgroups of interest

(*KRAS*, *TP53*, *SMARCA4*, *KEAP1*, *STK11, TMB).* **B.** Progression-free survival (PFS)

and **C.** Overall survival (OS) of Chemotherapy-IO vs IO in TMB low groups. **D.** PFS and

E. OS for the TMB high groups. **F.** PFS and **G.** OS of Chemotherapy-IO vs IO in

patients with *SMARCA4* mutations. Median survival times presented with confidence

intervals in brackets. TMB; tumor mutational burden. TMB high; TMB >=50th percentile,

TMB low; TMB <50th percentile. Mut; mutated. WT; wild type. Mut; mutated. WT; wild

type. Median survival times presented with confidence intervals in brackets.

Supplemental Figure Legends

Figure S1. Cohort assembly.

A total of N=3777 patients treated with either Chemotherapy-IO or IO treated between

1/10/17 and 9/8/20. Chemotherapy-IO; Combination PD(L)-1 blockade and platinum

chemotherapy. IO; single agent PD(L)-1 blockade.

Figure S2. Median PD-L1 and harmonized tumor mutational burden (TMB)

between chemotherapy plus PD-(L)1 blockade (Chemotherapy-IO) vs single-agent

PD-(L)1 blockade (IO) groups. A. Box plots of tumor PD-L1 expression and **B.** Median

TMB between Chemotherapy-IO and IO. ***p<0.001

Figure S3. Outcomes to chemotherapy plus PD-(L)1 blockade (Chemotherapy-IO)

vs single-agent PD-(L)1 blockade (IO) among patients with PD-L1 $\geq$90%. A.

Objective response rate, **B.** Progression-free survival and **C.** Overall survival.

Chemotherapy-IO and IO. Chemotherapy-IO; Combination PD(L)-1 blockade and

platinum chemotherapy. IO; single agent PD(L)-1 blockade.

Figure S4. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade

(Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in patients with PD-L1 1-

49%. A. Objective response rate, **B.** Progression-free survival (PFS), and **C.** Overall

survival (OS) among Chemotherapy-IO vs IO groups. **D.** PFS and **E.** OS analysis for

Chemotherapy-IO vs IO adjusting for co-variates of interest among different subgroups.

ECOG; Eastern Cooperative Oncology Group performance status. Median survival

times presented with confidence intervals in brackets. HR; hazard ratio. 95%CI; 95%

confidence intervals.

References

1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. *New England Journal of Medicine.* 2018;378(22):2078-2092.
2. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. *N Engl J Med.* 2019;381(21):2020-2031.
3. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021;22(2):198-211.
4. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. *New England Journal of Medicine.* 2020;383(14):1328-1339.
5. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. *New England Journal of Medicine.* 2018;378(24):2288-2301.
6. Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. *Nature Medicine.* 2022;28(11):2374-2380.
7. Reck M, Rodríguez–Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. *Journal of Clinical Oncology.* 2019;37(7):537-546.
8. Hellmann MD, Nathanson T, Rizvi H, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. *Cancer Cell.* 2018;33(5):843-852.e844.
9. Sehgal K, Gill RR, Widick P, et al. Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. *JAMA Network Open.* 2021;4(2):e2037120-e2037120.
10. Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. *Ann Oncol.* 2019;30(10):1653-1659.
11. Ricciuti B, Arbour KC, Lin JJ, et al. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. *J Thorac Oncol.* 2022;17(3):399-410.
12. Khaki AR, Glisch C, Petrillo LA. Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population. *JCO Oncology Practice.* 2021;17(9):583-586.
13. Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. *Ann Oncol.* 2020;31(5):599-608.

544   14.   Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated
545   Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization
546   Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor
547   Molecular Oncology. *J Mol Diagn.* 2015;17(3):251-264.
548   15.   Garcia EP, Minkovsky A, Jia Y, et al. Validation of OncoPanel: A Targeted Next-
549   Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
550   *Arch Pathol Lab Med.* 2017;141(6):751-758.
551   16.   Vokes NI, Liu D, Ricciuti B, et al. Harmonization of Tumor Mutational Burden
552   Quantification and Association With Response to Immune Checkpoint Blockade
553   in Non-Small-Cell Lung Cancer. *JCO Precis Oncol.* 2019;3.
554   17.   Ettinger DS, Wood DE, Aisner DL, et al. Non–Small Cell Lung Cancer, Version
555   3.2022, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National
556   Comprehensive Cancer Network.* 2022;20(5):497-530.
557   18.   Pérol M, Felip E, Dafni U, et al. Effectiveness of PD-(L)1 inhibitors alone or in
558   combination with platinum-doublet chemotherapy in first-line (1L) non-squamous
559   non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-
560   world data. *Annals of Oncology.* 2022;33(5):511-521.
561   19.   Curtis MD, Griffith SD, Tucker M, et al. Development and Validation of a High-
562   Quality Composite Real-World Mortality Endpoint. *Health Serv Res.*
563   2018;53(6):4460-4476.
564   20.   Griffith SD, Tucker M, Bowser B, et al. Generating Real-World Tumor Burden
565   Endpoints from Electronic Health Record Data: Comparison of RECIST,
566   Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-
567   World Progression in Non-Small Cell Lung Cancer. *Adv Ther.* 2019;36(8):2122-
568   2136.
569   21.   Arbour KC, Rizvi H, Plodkowski AJ, et al. Treatment Outcomes and Clinical
570   Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung
571   Cancer. *Clin Cancer Res.* 2021;27(8):2209-2215.
572   22.   Lin X, Wang L, Xie X, et al. Prognostic Biomarker TP53 Mutations for Immune
573   Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment
574   of Lung Adenocarcinoma. *Front Mol Biosci.* 2020;7:602328.
575   23.   Schoenfeld AJ, Bandlamudi C, Lavery JA, et al. The Genomic Landscape of
576   SMARCA4 Alterations and Associations with Outcomes in Patients with Lung
577   Cancer. *Clin Cancer Res.* 2020.
578   24.   al We. Welcome to the Tidyverse. Journal of Open Source Software.
579   2019;4(43):1686.
580   25.   Daniel D. Sjoberg KW, Michael Curry, Jessica A. Lavery and Joseph
581   Larmarange. Reproducable Summary Tabes with the gtsummary package. *The
582   R Journal.* 2021;13:1:570-580.
583   26.   *Modeling Survival Data: Extending the Cox Model.* 2000.
584   27.   Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line
585   treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a
586   multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet.*
587   2021;397(10274):592-604.

588   28.   Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via
589   Patient-to-Patient Variability without Drug Additivity or Synergy. *Cell.*
590   2017;171(7):1678-1691.e1613.
591   29.   Akinboro O, Vallejo JJ, Mishra-Kalyani PS, et al. Outcomes of anti-PD-(L1)
592   therapy in combination with chemotherapy versus immunotherapy (IO) alone for
593   first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with
594   PD-L1 score 1-49%: FDA pooled analysis. *Journal of Clinical Oncology.*
595   2021;39(15_suppl):9001-9001.
596   30.   Ricciuti B, Arbour KC, Alessi JVM, et al. Association of a very high tumor
597   mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved
598   clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels
599   in non-small cell lung cancer. *Journal of Clinical Oncology.*
600   2021;39(15_suppl):9018-9018.
601   31.   Song S, Nguyen V, Schrank T, et al. Loss of SWI/SNF Chromatin Remodeling
602   Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma. *Mol Cancer Res.*
603   2020;18(12):1777-1788.
604   32.   Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-Deficient Thoracic
605   Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated
606   Carcinomas Rather Than Primary Thoracic Sarcomas. *J Thorac Oncol.*
607   2020;15(2):231-247.
608   33.   Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with
609   tobacco smoking in human cancer. *Science.* 2016;354(6312):618-622.
610   34.   Wang X, Ricciuti B, Nguyen T, et al. Association between Smoking History and
611   Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. *Cancer Res.*
612   2021;81(9):2566-2573.
613   35.   Pérol M, Felip E, Dafni U, et al. Effectiveness of PD-(L)1 inhibitors alone or in
614   combination with platinum-doublet chemotherapy in first-line (1L) non-squamous
615   non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-
616   world data. *Ann Oncol.* 2022.
617

618
619

Figure 1

Figure 2

PD-L1 ≥ 50%

Figure 3

Never smokers

A.

p<0.001

Objective response rate (%): Chemo-IO 77%, IO 20%

B.

Chemo-IO median PFS 10.0 months (6.9, NR)
IO median PFS 2.2 months (1.4, 6.0)

Time (months) from start of first–line therapy

Number at risk

	0	6	12	18	24	30	36
Chemo/IO	17	13	6	5	4	4	3
IO	35	10	5	3	2	2	1

C.

Chemo-IO median OS NR (20, NR)
IO median OS 16 months (7.2, NR)

Time (months) from start of first–line therapy

Number at risk

	0	6	12	18	24	30	36	42	48
Chemo/IO	17	16	14	8	4	4	3	0	0
IO	35	23	19	13	9	8	6	3	2

Age <65

D.

p=0.004

Objective response rate (%): Chemo-IO 63%, IO 40%

E.

Chemo-IO median PFS 17 months (10, NR)
IO median PFS 4.6 months (3.4, 6.8)

Time (months) from start of first–line therapy

Number at risk

	0	6	12	18	24	30	36	42	48	54	60
Chemo/IO	52	35	25	21	17	11	6	3	1	0	0
IO	131	58	40	27	21	20	16	11	8	5	0

F.

Chemo-IO median OS 35 months (20, NR)
IO median OS 27 months (20,38)

Time (months) from start of first–line therapy

Number at risk

	0	6	12	18	24	30	36	42	48	54	60
Chemo/IO	52	41	33	26	22	15	7	3	1	0	0
IO	131	108	91	71	58	49	39	26	18	8	1

Figure 4

A.

Objective response rate (%) bar chart comparing Chemo-IO (blue) and IO (red):

	Chemo-IO	IO
KRASmut	38%	37%
KRASwt	49%	35%
TP53mut	46%	37%
TP53wt	40%	35%
SMARCA4mut	29%	48%
SMARCA4wt	45%	34%
KEAP1mut	35%	44%
KEAP1wt	46%	34%
STK11mut	27%	22%
STK11wt	48%	38%
TMB high	45%	41%
TMB low	42%	31%

TMB low

B.

Chemo-IO median PFS 6.2 months (4.7, 7.5)
IO median PFS 4.4 months (3.5, 6.0)
p=0.2

Number at risk

Chemo/IO	148	70	36	22	13	9	3	1	0
IO	155	61	35	21	16	16	11	8	3

C.

Chemo-IO median OS 15 months (13, 20)
IO median OS 19 months (16, 25)
p=0.15

Number at risk

Chemo/IO	148	109	73	45	29	18	7	1	0	0	0
IO	155	115	94	64	48	41	31	22	11	4	2

TMB high

D.

Chemo-IO median PFS 8.6 months (5.9, 12)
IO median PFS 6.6 months (4.3, 10)
p=0.3

Number at risk

Chemo/IO	115	58	40	27	16	13	8	3	0	0	0
IO	161	84	61	43	29	24	19	12	5	2	0

E.

Chemo-IO median OS 19 months (13, NR)
IO median OS 28 months (21, 45)
p=0.2

Number at risk

Chemo/IO	115	87	56	42	27	18	10	4	0	0	0	0	0
IO	161	125	107	84	67	55	47	30	15	9	3	2	2	2

SMARCA4mut

F.

Chemo-IO median PFS 4.6 months (2.0, 13.0)
IO median PFS 7.6 months (3.4, 15.0)
p=0.3

Number at risk

Chemo/IO	31	10	7	4	2	1	1	0	0
IO	40	22	15	10	9	9	6	3	1

G.

Chemo-IO median OS 12 months (7.6, NR)
IO median OS months 25 (16, NR)
p=0.06

Number at risk

Chemo/IO	31	23	11	8	3	2	1	0	0	0	0
IO	40	29	25	17	16	12	11	7	4	3	2